Porgaviximab Biosimilar – Anti-Zaire Ebola virus mAb – Research Grade

Description of Porgaviximab Biosimilar - Anti-Zaire Ebola virus mAb - Research Grade

Introduction

Porgaviximab Biosimilar, also known as Anti-Zaire Ebola virus mAb, is a research grade monoclonal antibody (mAb) that has shown promising results in the treatment of Ebola virus disease. It is a biosimilar of a well-known therapeutic antibody, ZMapp, which has been used in the past to treat patients infected with the Ebola virus. Porgaviximab Biosimilar is a highly specific and potent antibody that targets the Zaire strain of the Ebola virus, which is responsible for the majority of Ebola outbreaks in humans.

Structure of Porgaviximab Biosimilar

Porgaviximab Biosimilar is a chimeric monoclonal antibody, meaning it is composed of both human and non-human components. It is made up of two heavy chains and two light chains, which are linked together by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and is composed of four distinct domains: the variable domain, the constant domain, the hinge region, and the Fc region. The variable domain is responsible for binding to the Ebola virus, while the constant domain determines the antibody’s effector functions.

Activity of Porgaviximab Biosimilar

Porgaviximab Biosimilar works by binding to the glycoprotein on the surface of the Ebola virus, preventing it from entering and infecting host cells. The antibody’s variable domain specifically targets the Zaire strain of the Ebola virus, making it highly effective in neutralizing the virus. Once bound to the virus, Porgaviximab Biosimilar triggers a cascade of immune responses, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which lead to the destruction of the virus.

Application of Porgaviximab Biosimilar

Porgaviximab Biosimilar is primarily used as a therapeutic agent for the treatment of Ebola virus disease. It has been shown to be effective in both preclinical and clinical studies, with some studies reporting a survival rate of over 90% in patients treated with the antibody. Porgaviximab Biosimilar is administered intravenously and is typically used in combination with other treatments, such as antiviral drugs and supportive care.

In addition to its therapeutic use, Porgaviximab Biosimilar also has potential applications in research and development. The antibody can be used to study the structure and function of the Ebola virus, as well as to develop new diagnostic tools and vaccines. Its high specificity and potency make it a valuable tool for studying the virus and developing new treatments and preventive measures.

Conclusion

In summary, Porgaviximab Biosimilar is a chimeric monoclonal antibody that specifically targets the Zaire strain of the Ebola virus. Its unique structure and high specificity make it a potent therapeutic agent for the treatment of Ebola virus disease. In addition to its therapeutic use, Porgaviximab Biosimilar also has potential applications in research and development, making it a valuable tool in the fight against the Ebola virus.